What happened: Bayer AG shares fell about 5.0% to trade at 33.39 today after a significant procedural development threatened the $7.25 billion settlement intended to resolve a large swath of Roundup weed-killer claims. The pact, which had earlier received preliminary approval in Missouri state court, was transferred to the existing federal Roundup multidistrict litigation (MDL) in California after objectors successfully removed the matter from state court.
Federal judge’s stance: The settlement now sits before U.S. District Judge Vince Chhabria in the California MDL. Chhabria has publicly criticized the arrangement, using stark language to describe the deal as "filthy," "mind-boggling," "legally problematic," and beset by "major problems." Those remarks underscore a skeptical posture that could complicate any path to final approval in the federal forum.
Chhabria has previously made clear he views the MDL court as retaining oversight. In a May 6 order he wrote: "The agreement, even if it were to receive final approval from the state trial court and then somehow survive appellate review, would not prevent this Court from exercising its authority over the cases in this federal MDL." That ruling reinforces the prospect that even a state-court blessing would not bind the federal MDL court.
Objectors and formal challenges: In late May, attorney Ashley Keller and the Tennessee law firm Frazer PLC filed formal objections in Missouri’s Circuit Court, describing the proposed resolution as "grossly inadequate and unfair." Those filings, together with the removal of the settlement into federal court, constitute active legal pressure points on the deal.
Market context: The legal turmoil arrived against a backdrop in which Germany’s DAX had already been under pressure in the prior session, and Bayer was one of the index’s weaker performers even before today’s setback. At the prior close German stocks were mixed, with the DAX down about 0.44%, and losses in the Pharmaceuticals and Healthcare sector contributing to the index’s decline. Across the Atlantic, U.S. benchmarks - the S&P 500, Dow Jones and NASDAQ - were trading in a narrow, near-flat range and offered little macro support.
Analyst view and investor calculus: Jefferies recently kept a "Hold" rating on Bayer with an updated price target of 80. Although that view does not add an upside catalyst amid the legal uncertainty, it provides a reference point for some market participants weighing the stock. Investors are now recalibrating the probability that the $7.25 billion settlement will survive legal challenge intact and what a drawn-out resolution could mean for Bayer’s balance sheet and free cash flow.
Timing and scope of the settlement: The proposed settlement includes an opt-out deadline for class members set for June 4, 2026, and would allow funding to be spread over as long as 21 years. The agreement formed part of Bayer’s strategy to contain the extensive litigation that followed its 2018 acquisition of Monsanto. Bayer has already expended more than $10 billion addressing Roundup claims, and approximately 65,000 cases remain pending.
Why the market moved: The combination of a federal judge who has signaled hostility toward the deal, formal objections lodged in state court, and an approaching opt-out deadline has heightened investor concern that the hoped-for legal closure may not materialize on the timetable or terms Bayer had anticipated. With the stock trading well below its 52-week high of 49.78 and the settlement’s final approval hearing scheduled for July 9, 2026, market participants appear to be pricing in a lower probability that the agreement will stand as written.
Summary: A procedural transfer of a Missouri-approved $7.25 billion Roundup settlement to the federal MDL in California, combined with pointed criticism from Judge Vince Chhabria and formal objections by plaintiffs' counsel, prompted a near 5.0% drop in Bayer shares to 33.39. The developments raise questions about the settlement's viability and increase the risk of a prolonged litigation timeline.